Birth Control Among US Therapies at Risk From 250% Tariffs (1)

US President Donald Trump’s threat of imposing tariffs as high as 250% on pharmaceutical imports is putting cheap supplies from Indian drugmakers at risk, with commonly prescribed oral contraceptives at the top of the list.

Approximately 65% of all birth control pill prescriptions in the US last year were manufactured by just two India-based companies, Glenmark Pharmaceuticals Ltd. and Lupin Ltd., according to a Bloomberg News analysis of data provided by health care intelligence firm Symphony Health.

While dependence on Indian imports and a narrow supply base is particularly acute for the birth control pills, some other drug ...